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blood progenitors and that infusion of expanded cells together with
a non-cultured cord blood unit will likely provide rapid engraft-
ment by the former cells and still allow for stable long-term
engraftment by the latter cells. The potential efﬁcacy of Delta1-
cultured CB progenitors in contributing to rapid early engraftment
in clinical CBT is currently being tested in a Phase I clinical trial.
To date, two patients with hematologic malignancy (AML) have
received Delta1-cultured CB cells with a second unrelated and
unmanipulated donor CB graft after undergoing a myeloablative
preparative regimen with cytoxan, total body irradiation and ﬂu-
darabine, and post grafting immunosuppression with cyclosporin
and MMF. Upon harvest of the cultured cells at 16 days post
culture initiation, the CD34 fold expansion was 210 and 174 and
the fold expansion of total cell numbers, 791 and 740. The kinetics
and durability of hematopoietic reconstitution and the relative
contribution of the expanded and non-manipulated grafts over
time will be determined by chimerism analysis in the marrow
(unsorted) and peripheral blood CD3, CD33, CD56, CD14 and
CD19 cell fractions, beginning on day 7 post transplant. Prelim-
inary data from the ﬁrst 2 patients demonstrated early myeloid
recovery at a time when engraftment due to infusion of 2 non-
cultured units would not be expected, with both patients achieving
an ANC of 100 by day7 post transplant. Engraftment (deﬁned as
the ﬁrst of three consecutive days with an ANC 500) was
achieved at day 9 and day 16, which compares favorably to our
own center’s data demonstrating a median time to engraftment of
27 days (N10) following conventional double unmanipulated
CBT and published results reporting a median time to engraftment
of 23 days (Barker, J et al, Blood, 105(3):1343-1347, Feb 2005).
Furthermore, the early myeloid engraftment seen in these patients
was determined to be 100% derived from the expanded CB graft.
Continued analysis of peripheral blood sorted cell fractions re-
vealed loss of contribution to engraftment in all cell populations
from the expanded cells by day 21 in the ﬁrst patient. In contrast,
the second patient continued to show contribution of engraftment
in the CD14, CD56 and CD19 sorted cell fractions at day 100 post
transplant. Furthermore, the patients treated to date have also
experienced a reduction in the expected regimen related toxicities
(e.g., mucositis, fevers, need for nutritional support), and the sec-
ond patient was discharged from the hospital on day 15 post
transplant. These two patients provide compelling data that clini-
cally relevant expansion of at least a short term repopulating cell is
feasible and may result in signiﬁcant decrease in delayed engraft-
ment post CBT and potentially a reduction of regimen related
toxicities.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Elizabeth J. Shpall, Simon Robinson, Marcos de Lima, Krishna Kom-
anduri, John D. McMannis, Laurence Cooper, Laura Worth, Chitra
Hosing, Ian K. McNiece,* Richard E. Champlin The MD Anderson
Department of Stem Cell Transplantation and Cellular Therapy, Hous-
ton, Texas and the Johns Hopkins Oncology Center, Baltimore, MD*
Cord blood (CB) is rapidly becoming an important source of
hematopoietic stem and progenitor cells (HSPC) for transplant for
cancer patients. Advantages associated with the use of CB include
the ready availability, increased ethnic diversity of the tissue (ethnic
minorities are poorly represented in current blood and bone mar-
row registries) and a reduced risk of graft-versus-host disease
(GvHD) at transplant. One major disadvantage associated with the
use of CB is delayed platelet and myeloid engraftment observed
following transplant when compared to the transplant of growth
factor-mobilized peripheral blood (mPB) or bone marrow (BM)
HSPC. Delayed engraftment is thought to be due, at least in part,
to the relatively low cell dose available for transplant and limits
effective CB transplantation to patients 70 kg. There also appear
to be intrinsic differences between CB-derived and peripheral
blood or bone marrow-derived HSPC, which may also contribute
to delayed engraftment. An approach for ex vivo expansion is the
co-culture of CB cells with bone marrow mesenchymal stem cells
(MSCs) which provide a microenvironment for the complex mo-
lecular cues that direct self-renewal/proliferation and regulate the
differentiation and maturation of hematopoietic progeny. Mc-
Niece et al have reported impressive expansion of CB on MSC
stroma. Robinson et al have shown superior expansion of CB in
MSC co-cultures when compared to liquid cultures of the same
CD133 CB fractions. Infusion of MSCs has been shown to
promote engraftment of human CD34 cells in NOD/SCID mice
and fetal sheep. Importantly MSC have been shown to have im-
munomodulatory activity which may reduce graft versus host dis-
ease and enhance engraftment in patients. In pre-clinical studies
performed by Robinson et al at MD Anderson, MSCs were isolated
from bone marrow mononuclear cells and conﬂuent monolayers
generated in 175 cm2 tissue culture ﬂasks. The monolayers were
maintained by a weekly medium change with MSC culture medium
until ready for use. At least 3 passages performed to ensure removal
of residual donor hematopoiesis. Non-selected, washed, CB sam-
ples were diluted in ex vivo expansion medium containing 20%
(v/v) FBS (HyClone) plus 100ng/ml each of G-CSF (Amgen), SCF
(R&D Systems, Minneapolis, MN) and thrombopoietin (TPO)
(R&D Systems) and plated over the pre-established conﬂuent
MSC monolayers. Speciﬁcally, cord blood cells were plated as a
10% fraction and placed in 50 mls of ex vivo expansion medium
over pre-established conﬂuent MSC monolayers in 175 cm2 tissue
culture ﬂasks. After 7 days at 37°C, non-adherent cells were re-
moved and a proportion diluted 1:15 for subsequent culture in ex
vivo expansion medium in either 75 cm2 tissue culture ﬂasks or
1-liter Teﬂon-coated culture bags (American Fluoroseal Corp.) for
an additional 7 days (14 days total). The original co-culture ﬂasks
(containing the MSC) were re-fed with 50 mls of expansion me-
dium and also cultured for an additional 7 days. At day 14, non-
adherent cells from both cultures were harvested and assayed for
yield of TNC, CFU, CD133, CD34 and CAFCwk2-6 data.
The liquid culture method employing CD133 CB currently
being studied clinically at MD Anderson was compared to the
MSC-cord blood co culture technique. The yield of total nucleated
cells, CFU, CD34 and CD133 cells as well as CAFCwk2-6 in
the CB-MSC co-culture method was signiﬁcantly higher than that
of the current liquid culture method. These data suggest that
MSC-cord blood could potentially produce more rapid engraft-
ment than the liquid expansion methods.
MD Anderson Mesenchymal Stem Cell - Cord Expansion Pro-
tocol #05-0781 (IND 13, 034). Based on the data described above,
a clinical trial will be conducted. In this study a family member will
serve as the marrow-derived mesenchymal stem cell (MSC) donor
for this trial; 50 ml of marrow will be aspirated from that donor and
the MSCs generated in 10 ﬂasks (takes 21 days). One of two
designated CB units will then be thawed and placed into the ﬂasks
containing the conﬂuent layers of MSCS with the growth factor
regimen used in our current liquid culture protocol (SCF, FLT3,
G-CSF and TPO). After 7 days at 37°C, the non-adherent cells
will be removed from each ﬂask, placed into each of ten 1-liter
Teﬂon-coated culture bags and cultured for an additional 7 days
(14 days total). Patients will be admitted to the hospital on day -9
for hydration and receive the designated preparative regimen on
days8 through2. On day 0, the unmanipulated CB unit will be
infused in the morning followed by the expanded CB cells (from
the bags and the remaining CB-MSCs in the ﬂasks). This is a
single-arm study with an accrual target of 35-40 patients. The
primary endpoint of the trial is time to engraftment. Accrual is
planned to begin in May, 2007.
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THERAPEUTIC MANIPULATION OF THE STEM CELL NICHE
David Scadden, MD Harvard Stem Cell Institute, Massachusetts Gen-
eral Hospital, Boston, MA
Altering stem cell function in normal and disease settings has
implications for regenerative medicine and for the current practice
of stem cell transplantation. Emphasis has generally been placed on
the stem cell as a cell autonomous unit, however in vivo these cells
are clearly responsive to distinct physiologic cues provided by their
microenvironment. The ability of speciﬁc anatomic sites to provide
regulatory input is what deﬁnes these sites as stem cell niches and
offers a distinct set of targets for developing stem cell based
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therapeutics. We have attempted to deﬁne elements of a hemato-
poietic stem cell niche by focusing on the endosteal surface where
some stem cells are known to localize in the adult mammal. Using
genetic models altering features of the bone or the stem cell
response to bone elements, we and others have begun to charac-
terize components of the endosteal stem cell niche. The molecular
interactions governing the effects of the niche provide potential
targets for drug based therapies and some of these can simply
re-purpose existing compounds. Using PTH analogues developed
for osteoporosis for example has been shown to alter the outcome
of both stem cell harvesting and engraftment procedures in the
mouse model. The application of these models to human trials has
begun. Targeting the niche may modify the complex systems in
which stem cells reside and provides a distinct therapeutic ap-
proach to stem cell based medicine.
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MANAGEMENT OF PRIMARY GRAFT FAILURE AFTER UNRELATED UM-
BILICAL CORD BLOOD TRANSPLANTATION
Ka Wah Chan, Michael S. Grimley, Candace Taylor, Donna A. Wall
Division of Pediatric Stem Cell Transplantation, Texas Transplant
Institute and Methodist Children’s Hospital, San Antonio, Texas
Primary graft failure (GF) is a major risk in unrelated donor
umbilical cord blood transplant (UCBT). We retrospectively re-
viewed data from 100 consecutive patients transplanted at Texas
transplant Institute between 3/2001 and 8/2006, and analyzed the
risk factors and the management of this complication. Their me-
dian age was 5.3 (range 0.1-8.4) years, and median weight 22 (range
4-85) kg. Seventeen did not achieve myeloid recovery; deﬁned as
an absolute neutrophil count (ANC)  500/	l by day 28. Of these,
8 died early from transplant-related complications or persistent
leukemia. Nine patients received 2nd UCBT in 33 to 95 (median
55) days. Their diagnoses were: ALL (3), MDS (1), HLH (2), SAA
(1), CD40L deﬁciency (1). Intensive immunosuppression condi-
tioning was used: the commonest regimen being ﬂudarabine
175mg/m2, cyclophosphamide 50mg/kg, TBI 2 Gy, 
 ATG (6
patients). Median cell dose for 2nd UCBT was 7.8  107/kg.
Degree of HLA matching was similar to 1st UCBT. 8/9 evaluable
patients engrafted; ANC 500/	l at a median of 15 (range 5-64)
days, platelets  20,000 /	l at a median of 92 (range 24 to 137)
days after the 2nd UCBT. All achieved complete donor chimerism.
As of 2/28/2007, 5/9 patients are alive, 758-1,828 (median 1,224)
days after 2nd UCBT. EBV-lymphoproliferatve disorders devel-
oped in 2 patients. Late infections were common: viral infections
included: BKV(2), HHV-6(2), CMV (2); and adenovirus (1). These
were severe and protracted. Acute graft-versus-host disease
(GVHD) diagnosed in 3/ 8, and chronic GVHD in 6/8 patients.
Three patients remain on immunosuppressive therapy. Chimerism
study by PCR was predictive of subsequent engraftment: any result
showing  5% donor cells was associated with irreversible graft
loss. In conclusion, early 2nd UCBT is a feasible treatment for
primary GF. Using an immunosuppressive preparative regimen
lead to reliable engraftment, but the incidence of chronic GVHD
and viral reactivation were high.
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DIRECT INTRA BONE TRANSPLANT OF UNRELATED CORD BLOOD
CELLS IS ASSOCIATED WITH FAST AND COMPLETE HEMATOLOGIC
RECOVERY
A. Ibatici, A.M. Raiola, F. Gualandi, N. Sessarego, A. Parodi, S. Pozzi,
M. Gobbi, M. Corselli, M. Podesta`, G. Piaggio, A. Bacigalupo and F.
Frassoni Centro Cellule Staminali e Terapia Cellulare, Divisione Ema-
tologia, Clinica Ematologia, Ospedale San Martino, Genova, Italy
Background. Cord blood transplants (CBT) are associated with
delayed or failed engraftment in a signiﬁcant proportion of pa-
tients. Two of our previous observations suggested (i) that, in the
animal model, direct intra-bone (i.b.) injection of hematopoietic
cells improves seeding efﬁciency and (ii) that the delayed engraft-
ment was not related to an insufﬁcient number of hematopoietic
stem cells but rather to a reluctance to differentiation and matu-
ration. Methods. Unrelated CB (4/6 or 5/6 HLA antigen matched)
were selected for 20 consecutive patients. Median cell dose was
2.6  10∧7/kg (range 1.6-3.5). CB cells were concentrated in a
total volume of 20 ml and infused in the supero-posterior iliac crest
(SPIC) under rapid general anesthesia (10 minutes with propofol).
Patients median age was 38 years (18-63), 16 had acute leukemia,
2 chronic myeloid leukemia, 2 Hodgkin disease. Sixteen patients
had refractory or advanced disease, whereas 4 had high risk ﬁrst
remission leukemia. Most patients (n16) were prepared with
conventional CY-TBI. Results. The infusion of cells i.b. in supero-
posterior iliac rest (SPIC), in the operating room, under short
general anaesthesia, was uneventful. All patients engrafted. Cumu-
lative incidence of neutrophil and platelet engraftment was 100%
at 50 days. Median for neutrophil engraftment (0.510∧9/l) was
day 23 (14-40), whereas for platelets (2010∧9/l) it was day 38
(range 22-47). Three patients are not evaluable because they died
within day 10 from transplant. Two patients relapsed and two died
of infection and multiorgan failure. Twelve patients are alive and
well in hematologic remission at a median follow up of 6 months
(range 2-11). 100% donor chimerism was documented since 30
days onward after transplant, including those in which CB cells
were injected monolaterally in one SPIC. From day60, CFC and
LTC-IC had already reached the lower values of the range of
normal individuals in bilateral sites. This is particularly relevant
considering that hemopoietic progenitor reconstitution remains
deﬁcient years after allo-transplant. Thus, direct injection of CB
cells in the bone marrow spaces produces in situ proliferation and
maturation, rapid recovery of peripheral blood counts, and early
recirculation of stem cells to other un-injected bone marrow sites.
Acute GvHD grade II was seen in 2/20 patient (10%). Since
lymphocyte trafﬁcking is known to be an essential part of immune
response, two combined factors might contribute: (i) injected T
cells come immediately in direct contact with mesenchymal stem
cells (MSC) and osteoblasts which are known to be potent immu-
nomodulators; (ii) the T cells present in the graft do not reach
primarily in the lymphatic organs, where they would be immedi-
ately confronted with host antigen presenting cells, as it probably
occurs after intra-venous injection. Conclusion. This study shows
that CB cells injected directly into the iliac crests are associated
with fast and complete hematologic recovery and almost absent
acute GvHD. The direct intra-bone transplant of CB cells could
now be offered to many more adult patients. This may change our
policy of hemopoietic cell transplants.
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A “NO-WASH” ALBUMIN-DEXTRAN DILUTION STRATEGY FOR UMBIL-
ICAL CORD BLOOD (UCB) THAW FOR ADOLESCENT AND ADULT UCB
TRANSPLANT RECIPIENTS: SUPERIOR TO WASH?
Juliet N. Barker, Rebecca Hawke, Allison Schaible, Michelle Abboud,
Nancy H. Collins, and Andromachi Scaradavou
The albumin-dextran wash, appropriate for small children, has
been adopted for adult UCB transplant (UCBT) recipients as a
matter of convention. However, an alternative strategy dilutes the
product in albumin-dextran without centrifugation. This “no
wash” technique could be advantageous for adolescents and adults
in whom even small cell losses may be clinically signiﬁcant, and
who are likely to tolerate small amounts of DMSO. Further, unlike
a bedside thaw, albumin-dextran dilution is still conducted in the
controlled environment of the Cytotherapy Laboratory. There-
fore, we conducted a prospective study of albumin-dextran dilution
in clinical UCBT. UCBT recipients  40 kg were eligible. Our
hypothesis was that the “no wash” thaw will be comparable to wash
in terms of post-thaw TNC yield and engraftment. To date, 37
units have been thawed using albumin-dextran dilution and trans-
planted into 19 patients (all received double unit grafts 4-6/6 HLA
matched, one red cell containing unit was washed). All patients
(median age 36 years, range 10-65 years; median weight 77 kg,
range 49-111) had hematological malignancies. A 5:1 Gen-
tran®40/ 25% albumin solution was used. Red cell depleted units
(n 35) were thawed to a dilution 5.5 fold [median ﬁnal volume
200 mls (range 200-500mls)]. The larger volume red cell contain-
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